Paradigm | Jotup

NAIC's Paradigm Changers Internship Program is Building a Pathway for Women to Pursue Careers in Alternatives

Retrieved on:

Giovedì, Maggio 2, 2024

Investment, PAI, Woman, American Investment Council, National Association, PAI Partners, Paradigm, NAIC, GCM Grosvenor

Launched in 2021, NAIC's Paradigm Changers Internship Program was designed to create opportunities for ethnically diverse women to explore careers in the alternatives industry through a combination of training and career development sessions and an immersive summer internship.

Key Points:

Launched in 2021, NAIC's Paradigm Changers Internship Program was designed to create opportunities for ethnically diverse women to explore careers in the alternatives industry through a combination of training and career development sessions and an immersive summer internship.
The Paradigm Changers Internship Program kicked off in March in Washington, DC, where participants got to know each other and learned more about the program.
We are excited to announce the 15 women who were selected to participate in NAIC's 2024 Paradigm Changers Internship Program:
Oluseyi Yoloye is awaiting graduate school commitment.
"NAIC's Paradigm Changers Program provides a pathway for diverse women to access opportunities in an industry that has been uniquely difficult to enter.

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Retrieved on:

Martedì, Aprile 16, 2024

Sale, Prospectus, Investment, Morgan Stanley, Stifel, SVB Securities, Research, OrbiMed, Exercise, Paradigm, CGEM, Therapy, Security (finance)

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.001 per share. Cullinan expects to receive gross proceeds from the offering of approximately $280.0 million, before deducting placement agent fees and other offering expenses.

Key Points:

Cullinan expects to receive gross proceeds from the offering of approximately $280.0 million, before deducting placement agent fees and other offering expenses.
The private placement is expected to close on or about April 18, 2024, subject to the satisfaction of customary closing conditions.
Morgan Stanley, TD Cowen, and Leerink Partners acted as lead placement agents for the private placement.
Stifel acted as a placement agent and Wedbush & Co., LLC and BTIG acted as co-placement agents for the private placement.

Forbes Names Avangrid Among America’s Best Employers for Diversity

Retrieved on:

Martedì, Aprile 23, 2024

Avangrid, Inc. (NYSE: AGR), a leading sustainable energy company and a member of the Iberdrola Group, has been named to Forbes list of America’s Best Employers for Diversity 2024 .

Key Points:

Avangrid, Inc. (NYSE: AGR), a leading sustainable energy company and a member of the Iberdrola Group, has been named to Forbes list of America’s Best Employers for Diversity 2024 .
This annual list researches and reviews companies’ diversity, equity and inclusion (DEI) best practices and conducts anonymous employee surveys.
“We’re focused on creating a workplace where talented and committed employees build meaningful, long-term careers,” said Pedro Azagra, Avangrid CEO.
The participants were asked to anonymously rate their employers on the organization’s approach to diversity as it pertains to such criteria as age, gender, ethnicity, disability, sexual orientation and general diversity.

Paradigm for Parity® Names Nadine Bullock-Pottinga as Next CEO

Retrieved on:

Lunedì, Aprile 22, 2024

Quince, Marketing, Woman, Bank, Paradigm, Veteran, Bank of America, Management

NEW YORK, April 22, 2024 /PRNewswire/ -- Paradigm for Parity (P4P), a nonprofit dedicated to closing the gender gap in business leadership, today announced that Nadine Bullock-Pottinga will be its next CEO, effective May 1st, 2024.

Key Points:

Nadine is an executive leader with over 20 years in the nonprofit sector.
"We are delighted to have Nadine at the helm of our executive management.
"Paradigm for Parity has emerged as a premier organization to drive sustainable progress in closing the gender leadership gap," stated incoming CEO Nadine Bullock-Pottinga.
Quince has been named a Co-chair and remains a member of the Board of Directors as well as a spokesperson for Paradigm for Parity.

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on:

Martedì, Aprile 9, 2024

ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points:

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
“We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
Jefferies acted as the exclusive placement agent in the private placement.

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on:

Mercoledì, Aprile 3, 2024

Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points:

Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
“Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on:

Mercoledì, Aprile 3, 2024

Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points:

Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
“Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

Proprio Announces Strategic Partnership with Biedermann to Revolutionize Surgery Through AI-Powered Guidance

Retrieved on:

Martedì, Aprile 9, 2024

Partnership, Patient, Paradigm, 3D, Radiation exposure, AI, Surgeon, Workflow, Health, Medical device

SEATTLE, April 9, 2024 /PRNewswire/ -- Proprio, the leader in AI-powered surgical technology, today announced a landmark multi-phase partnership with the Biedermann Group, the prominent innovator in next generation spinal implant systems and procedural solutions. Initially, the companies will collaborate to integrate Biedermann's advanced spinal implants with Proprio's Paradigm system, which harnesses AI, computer vision, and augmented reality to provide unprecedented real-time visualization and guidance to surgeons in the operating room.

Key Points:

By capturing and analyzing vast amounts of data, Paradigm aims to dramatically improve surgical precision, workflow, decision-making, and ultimately patient outcomes.
Proprio's initial focus on spinal surgery is driven by the immense need for technological advancements in this field.
"This collaboration with Biedermann will further increase the Paradigm platform's unique capabilities to positively impact patient results through data-based planning and performance.
We are excited to accelerate this critical partnership with Biedermann so that clinicians and patients alike can benefit from our advanced surgical guidance capabilities," said Gabriel Jones, CEO and Co-founder of Proprio.

Paradigm by Puloli™ Transforms Methane Monitoring with its Solution-as-a-Service (SaaS)

Retrieved on:

Martedì, Aprile 9, 2024

TDLAS, Internet of things, SAN, M series, Paradigm, Software, Workflow, Software as a service, Data collection, Methane, Video game

The M-Series is a perfect product-market fit for Puloli's networking solution vertically integrated with IoT applications in methane monitoring-as-a-service.

Key Points:

The M-Series is a perfect product-market fit for Puloli's networking solution vertically integrated with IoT applications in methane monitoring-as-a-service.
Paradigm uses state-of-the-art TDLAS methane sensors, anemometers, and edge compute devices to guarantee top-quality components for seamless workflow and data collection.
Performance expectations are shifting in methane monitoring, and Paradigm by Puloli™ stands at the forefront with its M-Series™.
By addressing the industry's pain points, Paradigm has modernized methane monitoring and redefined the standards of accuracy, reliability, and cost-effectiveness.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on:

Mercoledì, Aprile 3, 2024

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points:

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
“This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”